Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health. The findings shed new light on the impact, prevalence and treatment concerns related to uterine leiomyomas (fibroids), which affect up to 80 percent of women by age 50.
"We conducted this survey to better understand the experience and needs of women with fibroids," says Elizabeth A. Stewart, M.D., lead author and gynecologic surgeon at Mayo Clinic. "Many people are unaware that the vast majority of women will experience uterine fibroids in their lifetime and that this condition can cause significant morbidity for those who are symptomatic."
The survey assessed diagnosis, information-seeking behaviors, attitudes about fertility, impact on work and treatment preferences among women living with uterine fibroids for an average of nearly nine years. The researchers found that women delayed seeking treatment an average of 3.6 years, with 32 percent of women waiting more than five years. Most women reported fears associated with their fibroids, including being afraid that the fibroids will grow (79 percent) and that they will need a hysterectomy (55 percent), as well as fears regarding relationships, sexual function, body image, loss of control and hopelessness. Almost two-thirds (66 percent) of women were concerned about missed days from work due to their symptoms, and 24 percent of employed respondents felt that their symptoms prevented them from reaching their career potential. The vast majority said they prefer a minimally invasive treatment option that preserves the uterus.
Having better treatment options was particularly important to African-American women respondents, who experience the impacts on fertility earlier in their lives.
Uterine fibroids have a threefold increased relative risk and prevalence among African-American women and an earlier onset. The study demonstrated that the burden of uterine fibroids is even more extensive for African-American women than previously reported.
The researchers found that African-American women were significantly more likely to have severe or very severe symptoms, including heavy or prolonged menses and anemia. African-American women more often reported that ﬁbroids interfered with physical activities and relationships and were more likely to miss days from work. Almost one-third (32 percent) of African-American women waited more than five years before seeking treatment for their fibroids, compared to only 17 percent of white women; similarly, while 43 percent of white women say they sought treatment within one year or less, only 20 percent of African-American women did the same. Future fertility and pregnancy were key concerns for African-American women; 71 percent said preserving the uterus was very important or important, versus 41 percent of white women.
"Uterine fibroids are a public health issue for African-American women," adds Dr. Stewart. "The cost and impact on their health has true public health implications for this community."
Uterine ﬁbroids are the leading cause of hysterectomy in the United States, with nearly half of hysterectomies being performed for uterine fibroids. Hysterectomy involves permanent removal of the uterus, which prevents fibroid recurrence but also results in loss of reproductive potential. A majority of survey respondents (51 percent) noted the importance of having a fibroid treatment option that allows them to keep their uterus and 84 percent stated they prefer a treatment option that does not involve any invasive surgery of any kind.
When presented with treatment descriptions, the majority of women (60 percent) rated focused ultrasound as their top treatment choice. Focused ultrasound treatment uses high-intensity sound waves to heat and destroy uterine fibroid cells while leaving surrounding tissue intact. It is an outpatient procedure that involves no incisions and enables many women to return to normal activity in one or two days.
The survey was funded by Fibroid Relief, a program of the Focused Ultrasound Foundation. The analysis was conducted with support from National Institutes of Health HD RC1063312 R01060503.
The impact of uterine leiomyomas: a national survey of affected women. Presented as an abstract at the 41st Global Congress on Minimally Invasive Gynecology of the American Association of Gynecologic Laparoscopists, Las Vegas, NV, Nov. 5-9, 2012.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Women's Health / Gynecology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Clinic, Mayo. "Fibroids have significant impact on quality of life, workplace performance." Medical News Today. MediLexicon, Intl., 28 Oct. 2013. Web.
5 Dec. 2013. <http://www.medicalnewstoday.com/releases/267912>
Clinic, M. (2013, October 28). "Fibroids have significant impact on quality of life, workplace performance." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267912.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.